CA3206537A1 - Use of neuroactive steroids for treatment of sexual dysfunction - Google Patents
Use of neuroactive steroids for treatment of sexual dysfunctionInfo
- Publication number
- CA3206537A1 CA3206537A1 CA3206537A CA3206537A CA3206537A1 CA 3206537 A1 CA3206537 A1 CA 3206537A1 CA 3206537 A CA3206537 A CA 3206537A CA 3206537 A CA3206537 A CA 3206537A CA 3206537 A1 CA3206537 A1 CA 3206537A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- administered
- acceptable salt
- sexual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142840P | 2021-01-28 | 2021-01-28 | |
| US202163142833P | 2021-01-28 | 2021-01-28 | |
| US63/142,840 | 2021-01-28 | ||
| US63/142,833 | 2021-01-28 | ||
| PCT/US2022/014075 WO2022165017A1 (en) | 2021-01-28 | 2022-01-27 | Use of neuroactive steroids for treatment of sexual dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3206537A1 true CA3206537A1 (en) | 2022-08-04 |
Family
ID=80787167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3206537A Pending CA3206537A1 (en) | 2021-01-28 | 2022-01-27 | Use of neuroactive steroids for treatment of sexual dysfunction |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240122945A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4284382A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2024507638A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230136599A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022214187A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3206537A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL304080A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023008726A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022165017A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| IL309922A (en) * | 2021-07-28 | 2024-03-01 | Sage Therapeutics Inc | Crystalline forms of a neuroactive steroid |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080080094A (ko) * | 2005-10-14 | 2008-09-02 | 하. 룬트벡 아크티에 셀스카브 | 에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법 |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| EP3068226A4 (en) * | 2013-11-11 | 2017-05-17 | Euthymics Bioscience, Inc. | Novel methods |
| SI3705488T1 (sl) * | 2014-05-29 | 2022-10-28 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporaba le-teh |
| PH12018501923B1 (en) * | 2016-03-08 | 2024-06-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3612186A1 (en) * | 2017-04-18 | 2020-02-26 | Marinus Pharmaceuticals, Inc. | Sustained release injectable neurosteroid formulations |
| WO2019241442A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| MX2021010744A (es) * | 2019-03-04 | 2022-01-18 | Praxis Prec Medicines Inc | Metodos para el tratamiento de la perimenopausia y la menopausia. |
| US20230210870A1 (en) * | 2020-06-08 | 2023-07-06 | Eliem Therapeutics, Inc. | Methods of treating female health conditions related to sex hormones |
-
2022
- 2022-01-27 WO PCT/US2022/014075 patent/WO2022165017A1/en not_active Ceased
- 2022-01-27 EP EP22704661.2A patent/EP4284382A1/en active Pending
- 2022-01-27 IL IL304080A patent/IL304080A/en unknown
- 2022-01-27 US US18/263,189 patent/US20240122945A1/en active Pending
- 2022-01-27 KR KR1020237025051A patent/KR20230136599A/ko active Pending
- 2022-01-27 JP JP2023540524A patent/JP2024507638A/ja active Pending
- 2022-01-27 CA CA3206537A patent/CA3206537A1/en active Pending
- 2022-01-27 MX MX2023008726A patent/MX2023008726A/es unknown
- 2022-01-27 AU AU2022214187A patent/AU2022214187A1/en active Pending
-
2026
- 2026-04-15 JP JP2026066979A patent/JP2026120717A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026120717A (ja) | 2026-07-22 |
| EP4284382A1 (en) | 2023-12-06 |
| MX2023008726A (es) | 2023-12-14 |
| US20240122945A1 (en) | 2024-04-18 |
| JP2024507638A (ja) | 2024-02-21 |
| KR20230136599A (ko) | 2023-09-26 |
| WO2022165017A1 (en) | 2022-08-04 |
| AU2022214187A9 (en) | 2024-05-23 |
| IL304080A (en) | 2023-08-01 |
| AU2022214187A1 (en) | 2023-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240122945A1 (en) | Use of neuroactive steroids for treatment of sexual dysfunction | |
| WO2022177718A1 (en) | Use of neuroactive steroid for treatment of sexual dysfunction | |
| US12409176B2 (en) | Methods of treating acute depression | |
| US8309535B2 (en) | Compositions and methods to treat recurrent medical conditions | |
| CZ99597A3 (en) | Use of combination of tricyclic or tetracyclic antidepressant, inhibitor of serotonin recatching or inhibitor of monoaminooxidase with a compound inducing neurotransmitter or with a neurotransmitter precursor for preparing a medicament for treating or prevention of sclerosis multiplex or other demyelinisation states | |
| TW201815385A (zh) | 用以治療中樞神經系統疾病之包含苯甲酸鹽化合物及鞣酸的組合物 | |
| KR20250004125A (ko) | 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법 | |
| KR20230131927A (ko) | 신경 정신 질환에 대한 항우울제와 덱스트로메토르판의조합 | |
| EP2642988A1 (en) | Method and composition for weight-gain management | |
| US11801256B2 (en) | Antidepressant-psilocybin co-treatment to assist psychotherapy | |
| CN111973592A (zh) | 治疗肌萎缩侧索硬化和神经病的方法 | |
| TWI922961B (zh) | 用於治療抑鬱症之組合物及方法 | |
| CZ301210B6 (cs) | Použití desoxypeganinu k ošetrování klinické deprese | |
| CN116847852A (zh) | 神经活性类固醇治疗性功能障碍的用途 | |
| US20140148465A1 (en) | Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine | |
| HK40100385A (en) | Combination of an antidepressant and dextromethorphan for neuropsychiatric conditions | |
| MXPA01001178A (es) | Metodos y composiciones para tratamiento y la prevencion de ciertos trastornos psiquiatricos y medicos mediante el empleo de la moclobemida. | |
| HK40060077A (en) | Domperidone compositions and methods for treating depression | |
| Cole | NEW THERAPEUTIC DIRECTIONS: PRESENTATIONS FROM THE MOVEMENT DISORDER SOCIETY'S 13TH INTERNATIONAL CONGRESS OF PARKINSON'S DISEASE AND MOVEMENT DISORDERS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241219 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241219 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241219 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251205 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251205 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260126 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260126 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED Effective date: 20260203 |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260223 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260223 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260226 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260226 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260226 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260226 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260227 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260514 |